Utrecht, The Netherlands and Philadelphia, USA – January 5, 2021 – LAVA Therapeutics B.V., a biotechnology company focused on applying its expertise in gamma-delta T-cell engagers to transform cancer therapy, today announced that Stephen Hurly, chief executive officer, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 4:55 p.m. ET.
“I’m looking forward to the opportunity to speak about our platform and pipeline,” said Mr. Hurly. “We believe 2021 will be a transformative year for LAVA as two of our programs are scheduled to enter the clinic, and we plan to continue expanding our pipeline.”
About LAVA Therapeutics B.V.
LAVA Therapeutics B.V. is developing a proprietary platform of bispecific engagers of gamma-delta T-cells for the treatment of solid tumors and hematologic malignancies. The company’s leading immuno-oncology approach activates Vγ9Vδ2 T-cells upon binding to membrane-expressed tumor targets. The company’s lead program, LAVA-051, is expected to enter Phase 1/2 clinical development in the first quarter of 2021. The company has established a highly experienced research and development team located in Utrecht, the Netherlands and Philadelphia, USA.
LAVA’s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for LAVA’s product candidates, and the potential use of our product candidates to treat various tumor targets. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical trials, changes in expected or existing competition, changes in the regulatory environment, the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity, failure of LAVA’s collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, among others. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.